Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria

Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria

Multidrug resistance in bacteria is an important issue and is increasing in frequency worldwide because of the limitations of therapeutic agents. From 2010 to 2019, 14 new systemic antibiotics received regulatory approval in the United States. However, few new antibiotics have been introduced in Rep...

Full description

Saved in:
Bibliographic Details
Published in:The Korean journal of internal medicine Vol. 37; no. 2; pp. 271 - 280
Main Authors: Hyo-jin Lee, Dong-gun Lee
Format: Journal Article
Language:Korean
Published: 대한내과학회 31-03-2022
Subjects:
Anti-bacterial agents
Antimicrobial stewardship
Carbapenem-resistant Enterobacteriaceae
Drug resistance
Methicillin-resistant Staphylococcus aureus
multiple
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multidrug resistance in bacteria is an important issue and is increasing in frequency worldwide because of the limitations of therapeutic agents. From 2010 to 2019, 14 new systemic antibiotics received regulatory approval in the United States. However, few new antibiotics have been introduced in Republic of Korea to combat multidrug-resistant pathogens. Here, we introduce six novel antibiotics for Gram-positive bacteria and five for Gram-negative bacteria approved by the United States Food and Drug Administration and the European Medicines Agency from 2009 to October 2021, and recommend that they be approved for use in Republic of Korea at the earliest possible date.
Bibliography:The Korean Association Of Internal Medicine
ISSN:1226-3303
2005-6648